FRANKFURT, GERMANY - Bayer AG announced today that it is stopping worldwide sales of Trasylol, used to reduce bleeding, because a Canadian clinical study found use of the drug could increase risk of death. Trasylol is an aprotinin, which blocks enzymes that dissolve blood clots. In October, the U.S. FDA allowed Trasylol to remain on the market despite studies that showed increased risk of death and other side effects.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.